Advancing cancer treatment through rigorous research and clinical validation
Our journey towards clinical validation
We are currently designing our animal studies to further validate the safety and efficacy of NovaSeal®. Our research team is working on comprehensive preclinical evaluations to ensure the highest standards of patient safety and treatment effectiveness.
Our development pipeline includes advanced formulations and next-generation embolic agents that will expand our treatment capabilities and improve patient outcomes across a broader range of conditions.
In vitro and in vivo validation studies completed
Designing comprehensive animal safety studies
Preparing for initial human safety studies
NovaSeal® Development
Preclinical Studies
Animal Studies
Clinical Trials
Currently active research studies
Completed research and validation studies
Comprehensive laboratory studies to validate the formulation and stability of NovaSeal® under various conditions.
Initial animal studies to evaluate the safety profile and basic efficacy of NovaSeal® in controlled environments.
Development and optimization of the bio-based formulation to ensure stability, efficacy, and safety.
Information for patients and healthcare providers
While we are not currently recruiting participants for clinical trials, we are actively preparing for future studies. Our first-in-human trials are expected to begin in 2025, and we will provide detailed information about participation opportunities as we approach that milestone.
We are committed to ensuring that our clinical trials are conducted with the highest standards of safety, ethics, and scientific rigor. All studies will be conducted in accordance with international guidelines and regulatory requirements.
Register your interest to receive updates about future clinical trial opportunities.